Locus Biosciences is revolutionizing the treatment of bacterial disease using its CRISPR-Cas3 technology to kill targeted bacteria while leaving the many species of good bacteria in the body unharmed. Listen to Kineticos Founder and CEO Shailesh Maingi and Paul Garofolo, CEO of Locus Biosciences as they discuss the past, present, and future of Locus Biosciences and the CRISPR-CAS3 enzyme. This conversation dives deep into how Paul was willing to take a major leap of faith that led to the discovery that the CAS3 enzyme, originally developed for agriculture applications, could ultimately revolutionize the treatment of bacterial disease.

Click Here to listen to Kineticos’ most recent podcast with Paul Garofolo, CEO of Locus Biosciences.